Form D · Other Health Care
Sherlock Biosciences, Inc.
Brighton, MA · CIK 0001774717
Offering snapshot reported Mar 15, 2022 · SEC filing
- Reported sold
- $80M Offering amount: $80M
- Investors reported
- 13 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Feb 28, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 15, 2022 | Initial | $80,000,013 | No comparison | 13 | SEC filing |
| Apr 25, 2019 | Initial | $32,759,240 | No comparison | 10 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-437356
Source: Form D, filed Mar 15, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| James Collins | Director |
| Bryan Dechairo | Director, Executive |
| Rahul Dhanda | Director, Executive |
| Issi Rozen | Director |
| Michael Rubin | Director |
| David Walt | Director |
Issuer details
Industry: Other Health Care (See others in industry)
Address:
40 Guest Street 3 Rd Floor
Brighton, MA, 02135
Brighton, MA, 02135